At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,034 enrolled
Drug / intervention
Terlipressin +2 moredrug
Likely dose
Terlipressin 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RCT for the Effect of Early Administration of Vasoactive Substances When Combined With Endoscopic Treatment in Acute Gastro-esophageal Variceal Bleeds: Comparisons Among Terlipressin, Somatostatin, and Octreotide
In Brief
A Phase 4 clinical trial evaluating Terlipressin, Somatostatin, and 1 other intervention for Variceal Bleeding, Cirrhosis. Completed, enrolled 1,034 participants across 1 site.
Detailed Summary
This study is performed to compare the efficacy of terlipressin, somatostatin, and octreotide in patients with variceal bleeding for the control of variceal bleeding in combination with endoscopic therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVariceal Bleeding, Cirrhosis
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
First PostedAug 2009
Primary CompletionMay 2010
TodayJul 2026
First PostedAug 26, 2009
Enrollment StartSep 1, 2006
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 16.8 years ago
Interventions
Terlipressindrug
loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days
Somatostatindrug
loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days
Octreotidedrug
loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days